Lessons From Europe: Orphan Drug Valuations Show Limits Of Cost Effectiveness

Biogen, Sanofi executives says US should learn from experience of European health technology assessment bodies as Institute for Clinical and Economic Review embarks on initiative to adapt its value framework to orphan drugs.